Landmark Trial Evaluating Potential FTD-GRN Therapeutic Completes Enrollment
Biotechnology company Alector Therapeutics announced on October 27 that it has completed enrollment for INFRONT-3, a Phase 3 clinical trial testing the safety and efficacy of the drug latozinemab as…
Read MoreThe Lived Experience of FTD: Anosognosia
The following article was written by Kevin Rhodes, a member of AFTD’s Persons with FTD Advisory Council. Council members like Kevin and Anne Fargusson, who contributed to this article, work…
Read MoreNovember 13, 2023 — Penn FTD Center Annual Caregiver Conference
The Penn FTD Center’s Annual Caregiver Conference is for those diagnosed with FTD, and their caregivers, family, and friends to access information and support. With presentations from leading experts in…
Read MoreAFTD Webinar: Grief, Loss, and Hope — Helping Families Living with FTD
FTD is the most common dementia for people under 60, and often occurs when there are teens or young adults still at home. An FTD diagnosis can bring feelings of…
Read MoreDoctor Living with FTD Discusses Life Post-Diagnosis in Interview
In an interview recently broadcast by Atlanta News First, former gynecologist Dr. Seth Stern discussed his work to spread awareness of FTD and his desire to live life to the…
Read MoreVolunteer Update: Giving Purpose to the Pain – Becoming an AFTD Ambassador and FTD Advocate
AFTD Ambassadors know the power of a single story and the healing potential of finding others who understand. Ambassadors are volunteer leaders who represent AFTD in communities across the U.S.,…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)